The release noted that brepocitinib demonstrated consistent benefits in preventing treatment failure across key subgroups, ...

Brepocitinib 45 mg once-daily achieved statistically significant benefit compared to placebo on the primary and all key secondary endpoints for each of CLARITY-1 and CLARITY-2, the two identical Phase ...

Carey said the take-home message is “if you have a patient who’s had MS and optic neuritis, and they call your office saying, ...

A study of 30.7 million US children revealed that pediatric uveitis incidence rose from 22 to 33 per 100,000 between 2016 and 2025.

Tuesday, July 7, 2026 11:37 AM The body’s immune system plays a critical role in recognizing and neutralizing foreign threats. Its immune response is divided into innate and adaptive immunity ...

The ADVISE trial has demonstrated adalimumab’s superior management of intermediate uveitis, posterior uveitis, or panuveitis requiring immunosuppression. Adalimumab treatment outperformed ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A 29-year-old woman was referred to Tufts Medical Center ...

Decreasing incidence and prevalence of uveitic glaucoma may be attributed to more cautious usage of corticosteroids and increased steroid-sparing immunomodulatory treatments, as well as earlier and ...

Researchers explored the TriNetX database to evaluate the growing rate of uveitis in the United States. A large study shows a higher prevalence of uveitis in the United States than was previously ...

An investigational Janus kinase 1 (JAK1) preferential inhibitor reduced the risk of treatment failure among patients with active noninfectious uveitis, the phase II randomized HUMBOLDT trial showed.